dockets: DEA-2026-1321

Regulatory dockets from Regulations.gov — containers for related documents and comments in a rulemaking proceeding.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id agency_id title docket_type last_modified object_id rin dkabstract category subtype keywords program short_title effective_date organization attrs_raw attr_source
DEA-2026-1321 DEA Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant From Schedule IV Into Schedule V (DEA1645) Rulemaking 2026-09-11T20:37:18Z 0b000064b942f6db Not Assigned The Drug Enforcement Administration proposes to transfer suvorexant ([(7R)-4-(5-chloro-1,3- benzoxazol-2-yl)-7-methyl-1,4-diazepan1-yl]-[5-methyl-2-(triazol-2- yl)phenyl]methanone), lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5- yl)oxymethyl]-2-(3-fluorophenyl)-N-(5- fluoropyridin-2-yl)cyclopropane-1- carboxamide), and daridorexant ([(2S)-2- (5-chloro-4-methyl-1H-benzimidazol-2- yl)-2-methylpyrrolidin-1-yl]-[5- methoxy-2-(triazol-2- yl)phenyl]methanone) from schedule IV to schedule V of the Controlled Substances Act. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule V controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle suvorexant, lemborexant, and daridorexant.               {"displayProperties": [], "keywords": null, "modifyDate": "2026-09-11T20:37:18Z", "dkAbstract": "The Drug Enforcement Administration proposes to transfer suvorexant ([(7R)-4-(5-chloro-1,3- benzoxazol-2-yl)-7-methyl-1,4-diazepan1-yl]-[5-methyl-2-(triazol-2- yl)phenyl]methanone), lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5- yl)oxymethyl]-2-(3-fluorophenyl)-N-(5- fluoropyridin-2-yl)cyclopropane-1- carboxamide), and daridorexant ([(2S)-2- (5-chloro-4-methyl-1H-benzimidazol-2- yl)-2-methylpyrrolidin-1-yl]-[5- methoxy-2-(triazol-2- yl)phenyl]methanone) from schedule IV to schedule V of the Controlled Substances Act. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule V controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle suvorexant, lemborexant, and daridorexant.", "agencyId": "DEA", "program": null, "shortTitle": null, "subType2": null, "title": "Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant From Schedule IV Into Schedule V (DEA1645)", "generic": null, "field1": null, "docketType": "Rulemaking", "petitionNbr": null, "rin": "Not Assigned", "organization": null, "legacyId": null, "subType": null, "category": null, "field2": null, "effectiveDate": null, "objectId": "0b000064b942f6db"} single_get

Links from other tables